Janssen to market TAF (tenofovir), emtricitabine and cobicistat, and darunavir combination for HIV/AIDS

Gilead and Janssen have amended a licensing agreement for the development and commercialization of a once-daily single tablet regimen for HIV containing Gilead�s TAF (tenofovir), emtricitabine and cobicistat, and Janssen�s darunavir. Under the amended agreement, Janssen will be responsible for further development of the regimen and, subject to regulatory approval, the manufacturing, registration, distribution and commercialization of the product worldwide.